Latest Working Capital News

Tetratherix Limited (ASX:TTX) has launched a $2 million share purchase plan offering eligible Australian and New Zealand shareholders the chance to buy shares at a 2% discount to recent trading prices. The non-underwritten SPP opens on 4 June and closes on 18 June 2026.

Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.

Helios Energy has raised $1.5 million through a share placement priced at $0.003 per share while extinguishing $100,000 of convertible note debt by issuing shares, bolstering working capital.

Altitude Minerals is gearing up for significant drilling campaigns in New South Wales and Nevada, backed by a recent $1.15 million capital raise to fund exploration and project advancement.

Biome Australia has inked a binding deal with Specialty Probiotics Australia to shift its Activated Probiotics manufacturing onshore, aiming to boost gross margins above 65% and streamline working capital within 18 months.

Dome Gold Mines (ASX:DME) is raising up to AUD 2 million through unsecured convertible notes to fast-track its Sigatoka feasibility study, mining lease application, and copper-gold exploration amid rising metal prices.

Green Cross Health plans to sell its Medical division, The Doctors, for NZ$270 million to Tend Health, refocusing on its pharmacy business. Completion hinges on shareholder approval expected by July 2026.

ASF Group has divested its non-core coking coal subsidiary for A$3.08 million, aiming to refocus capital towards growth and working capital enhancement.

ARC Funds Limited has secured $600,000 through a share placement priced at a 33% premium to its last traded price, aiming to strengthen its working capital and support growth initiatives.

Greatland Resources has locked in a $500 million debt facility with major banks, boosting liquidity to over $1.7 billion as it commits to developing its Havieron gold-copper project.

Senetas Corporation plans to return $3.5 million to shareholders via an equal capital reduction, reflecting confidence in its cash flow and growth prospects following recent strategic moves.

ParagonCare anticipates recovering up to 32.5% of its exposure to the insolvent Infinity Retail Pharmacy Group, while maintaining a steady FY26 earnings outlook amid cost pressures.